Form 4: Arrowhead Director Olukotun Acquires 7,819 RSUs
Insider Transaction Report
Arrowhead Pharmaceuticals Director Adeoye Y. Olukotun was granted 7,819 restricted stock units, increasing his direct beneficial ownership to 43,600 shares.
Summary
- Director Adeoye Y. Olukotun of Arrowhead Pharmaceuticals, Inc. (ARWR) acquired 7,819 shares of common stock.
- The acquisition occurred on December 16, 2025, at a price of $0 per share.
- These shares represent restricted stock units (RSUs) that will vest in one installment on the first anniversary of the grant date.
- Vesting is contingent upon Mr. Olukotun's continued service to the Issuer.
- Following this transaction, Mr. Olukotun directly beneficially owns 43,600 shares of common stock.
Sentiment
Score: 7
Explanation: The filing indicates a routine equity grant to a director, which is generally a neutral to slightly positive event as it aligns insider interests with shareholders. No negative financial or operational news is present.
Positives
- An insider, a Director, is increasing their beneficial ownership in the company, which can signal confidence in the company's future prospects.
- The grant of restricted stock units aligns the director's interests with long-term shareholder value through future vesting.
Negatives
- No direct negatives are apparent from this Form 4 filing, as it reports a routine equity grant.
Risks
- The vesting of the restricted stock units is subject to the reporting person's continued service to the Issuer, meaning the shares are not immediately owned and could be forfeited if service ceases before vesting.
Future Outlook
NA
Industry Context
NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 7,819 restricted stock units to Director Adeoye Y. Olukotun as part of his compensation package. | 12/16/2025 | Aligns director's long-term interests with shareholder value through equity ownership and service-based vesting. |
Stakeholder Impact
- Shareholders: Increased alignment of a director's interests with long-term shareholder value.
- Employees: No direct impact mentioned for general employees.
Next Steps
- The restricted stock units are expected to vest on the first anniversary of the grant date (approximately December 16, 2026), subject to continued service.
Key Dates
| Date | Description |
|---|---|
| 12/16/2025 | Date of transaction (acquisition of restricted stock units). |
| 12/16/2026 | Approximate vesting date for the restricted stock units (first anniversary of grant date). |
| 12/18/2025 | Date Form 4 was signed and filed. |
Keywords
Arrowhead Pharmaceuticals, ARWR, Adeoye Olukotun, Form 4, Insider Trading, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.